The Utility of A Transcriptomic Signature to Assess Atopic Dermatitis Treatment Outcomes
Previously our group identified a transcriptome signature (89ADGES) which can be used to monitor Atopic Dermatitis (AD) treatment outcomes. Herein, we hypothesized that expression of 89ADGES member genes can be predict treatment outcomes in response to topical corticosteroids (Betamethasone; BC) and calcineurin inhibitors (Pimecrolimus; PC).
Source: Journal of Allergy and Clinical Immunology - Category: Allergy & Immunology Authors: Debayoti Ghosh, Jonathan Bernstein, Tesfaye Mersha Source Type: research
More News: Allergy | Allergy & Immunology | Corticosteroid Therapy | Dermatitis | Dermatology | Elidel | Genetics